A plethora of protein language models have been released in recent years. Yet comparatively little work has addressed how to best sample from them to optimize desired biological properties. We fill this gap by proposing a flexible, effective sampling method for masked language models (MLMs), and by systematically evaluating models and methods both in silico and in vitro on actual antibody therapeutics campaigns. Firstly, we propose sampling with stochastic beam search, exploiting the fact that MLMs are remarkably efficient at evaluating the pseudo-perplexity of the entire 1-edit neighborhood of a sequence. Reframing generation in terms of entire-sequence evaluation enables flexible guidance with multiple optimization objectives. Secondly, we report results from our extensive in vitro head-to-head evaluation for the antibody engineering setting. This reveals that the choice of sampling method can have a substantial impact, motivating future research into this under-explored area.
Figures & tables
Approximation
Approximation + Gumbel
Model
Pearson
Spearman
Pearson
Spearman
ESM2-650M
0.964
0.940
0.735
0.727
AbLang2
0.869
0.869
0.752
0.729
ProteinMPNN
0.944
0.934
0.721
0.724
AbMPNN
0.927
0.850
0.726
0.615
Table 1: Approximate-vs-true PLL correlation over all 190 one-edit CDR-H3 variants of Trastuzumab ( τ=1 ).
Figure 1: ESM2-650M on the Trastuzumab CDR-H3 in silico evaluation. Color groups MasonCNN -guided methods with their lighter-shaded strong-oracle counterparts; linestyle indicates methodology (solid: ours; dashed: previous). [Left:] Mean predicted p(binder) vs edits from the seed; error bars depict 95%-bootstrap CIs. [Middle:] OASis × p(binder) Pareto frontiers. Faded dots show the underlying generated variants. [Top Right:] Mean p(binder) at each OASis percentile bucket, pooling across all edits. [Bottom right:] Pairwise H3-diversity violins restricted to “high-quality” variants — those with p(binder) > 0.5 AND OASis >0.245 , the Trastuzumab seed.
Figure 2: In silico metrics of quality and diversity for generated sequences: (A) predicted probability of synthesizability, (B) predicted melting temperature, (C) inter-seed pairwise diversity, and (D) intra-seed pairwise diversity.
Figure 3: In vitro results. For error bars around the success rate, we show 95% CIs via binomial test inversion. We depict the seed’s binding affinity and yield as a star on the x-axis.
Figure 4: Additional developability-related in silico evaluations of the sequences in the in vitro experiment. For each method, observations are split by successful synthesizability and binding.
Figure 5: Additional analysis of mutational preferences of different methods for the in vitro experiment. or each method, observations are split by successful synthesizability and binding.
Appendix figures & tables14 assets
Supplementary material from the paper’s appendix.
Appendix
Antibody
Sapiens
AbLang2
ESM2-650M
c143
0.941
0.955
0.930
mab114
0.924
0.935
0.896
mab114-uca
0.946
0.734
0.928
medi8852
0.837
0.925
0.878
medi8852-uca
0.878
0.282
0.888
regn10987
0.910
0.933
0.942
Appendix
Table 2: Approximate-vs-true PLL Spearman correlation, one-edit full VH+VL variants, over the seven-antibody panel from Hie et al. [2024] .
Antibody
Sapiens-CDR
AbLang2-CDR
ESM2-CDR
c143
0.971
0.930
0.892
mab114
0.933
0.859
0.880
mab114-uca
0.946
0.855
0.946
medi8852
0.828
0.881
0.906
medi8852-uca
0.778
0.675
0.895
regn10987
0.887
0.927
0.919
Appendix
Table 3: Approximate-vs-true PLL Spearman correlation over the seven-antibody panel from Hie et al., scoring only Chothia-defined CDR positions of the one-edit variant (while still conditioning on the full VH+VL sequence in the forward pass).
Antibody
Sapiens
AbLang2
ESM2
c143
1.878
1.955
3.301
mab114
2.107
1.949
3.967
mab114-uca
1.256
1.256
2.862
medi8852
1.607
1.761
3.719
medi8852-uca
1.212
1.156
3.653
regn10987
1.407
1.447
2.838
Appendix
Table 4: Per-residue pseudo-perplexity of the full seed sequence, over the seven-antibody panel from Hie et al. AbLang2 uniquely assigns extremely low perplexity to the UCA seeds, revealing memorization.
Antibody
Sapiens
AbLang2
ESM2
c143
88.4
1123.0
124.0
mab114
70.6
1141.9
74.8
mab114-uca
175.8
6837.3
175.1
medi8852
119.3
1420.3
87.0
medi8852-uca
173.3
8668.2
94.4
regn10987
150.1
3189.8
191.5
Appendix
Table 5: Geometric-mean pseudo-perplexity ratio of the seed’s local one-edit neighborhood (neighbor residue vs. seed residue), over the seven-antibody panel from Hie et al. AbLang2’s UCA likelihood peaks are surrounded by sharp cliffs in the local landscape.
Sapiens
AbLang2
ESM2
Antibody
Approx
True
Approx
True
Approx
True
c143
0.34
0.35
0.53
0.49
0.53
0.52
mab114
0.39
0.39
0.52
0.43
0.55
0.53
mab114-uca
0.08
0.08
0.33
-0.09
0.57
0.55
medi8852
0.24
0.19
0.45
0.30
0.52
0.51
medi8852-uca
0.11
-0.01
0.28
-0.35
0.54
0.52
Appendix
Table 6: Spearman correlation of each model’s approximate ( ≈ ) and true PLL against the DASM germline-bias-free selection score, per antibody, over the seven-antibody panel from Hie et al. [2024] . On the UCA seeds where AbLang2’s approximate-vs-true correlation is weakest, DASM agrees more with the approximation than with the true PLL – and is negatively correlated with the AbLang2 true PLL, indicating the “true” landscape reflects germline bias rather than biological selection.
Approximation
Pos. i sees at i
Pos. i sees at k
Total cost
Exact PLL
MASK
xk′ (child)
O(L4)
Double-mask
MASK
MASK
O(L4)
Masked-marginal
MASK
xk (template)
O(L3)
No-masking (child)
xi′ (visible)
xk′ (child)
O(L3)
No-masking (template)
xi (visible)
xk (template)
O(L2)
Appendix
Table 7: Comparison of PLL approximations for scoring all single-substitution neighbors during one step of beam search. Position k is the substitution site; position i=k is any other position. Each forward pass has cost O(L2) .
Figure 6: AbLang2 on the Trastuzumab CDR-H3 in silico evaluation. Color groups MasonCNN -guided methods with their lighter-shaded strong-oracle counterparts; linestyle indicates methodology (solid: ours; dashed: previous). [Left:] Mean predicted p(binder) vs edits from the seed; error bars depict 95%-bootstrap CIs. [Middle:] OASis × p(binder) Pareto frontiers. Faded dots show the underlying generated variants. [Top Right:] Mean p(binder) at each OASis percentile bucket, pooling across all edits. [Bottom right:] Pairwise H3-diversity violins restricted to “high-quality” variants — those with p(binder) > 0.5 AND OASis >0.245 , the Trastuzumab seed.
Figure 7: ProteinMPNN on the Trastuzumab CDR-H3 in silico evaluation, with (A) and without (B) the bound antigen. Color groups MasonCNN -guided methods with their lighter-shaded strong-oracle counterparts; linestyle indicates methodology (solid: ours; dashed: previous). [Left:] Mean predicted p(binder) vs edits from the seed; error bars depict 95%-bootstrap CIs. [Middle:] OASis × p(binder) Pareto frontiers. Faded dots show the underlying generated variants. [Top Right:] Mean p(binder) at each OASis percentile bucket, pooling across all edits. [Bottom right:] Pairwise H3-diversity violins restricted to “high-quality” variants — those with p(binder) > 0.5 AND OASis >0.245 , the Trastuzumab seed.
Figure 8: AbMPNN on the Trastuzumab CDR-H3 in silico evaluation, with (A) and without (B) the bound antigen. Color groups MasonCNN -guided methods with their lighter-shaded strong-oracle counterparts; linestyle indicates methodology (solid: ours; dashed: previous). [Left:] Mean predicted p(binder) vs edits from the seed; error bars depict 95%-bootstrap CIs. [Middle:] OASis × p(binder) Pareto frontiers. Faded dots show the underlying generated variants. [Top Right:] Mean p(binder) at each OASis percentile bucket, pooling across all edits. [Bottom right:] Pairwise H3-diversity violins restricted to “high-quality” variants — those with p(binder) > 0.5 AND OASis >0.245 , the Trastuzumab seed.
Configuration
Beam
Gibbs
Beam:Mason
Gibbs:Mason
Beam:Mason+OASis
ESM2-650M
0.98
0.44
0.92
0.49
0.98
AbLang2
0.26
0.40
0.99
0.49
0.64
ProteinMPNN (holo)
0.39
0.41
0.72
0.42
0.94
ProteinMPNN (apo)
0.22
0.35
0.51
0.43
0.98
AbMPNN (holo)
0.73
0.54
0.92
0.61
0.84
AbMPNN (apo)
0.57
0.40
0.88
0.47
0.78
Appendix
Table 8: Fraction of designs with oracle p(binder)>0.5 at E=6 edits, for the extended Trastuzumab models, both with (holo) and without (apo) the HER2 subdomain IV antigen.
Figure 9: Results from sweeping beam size (A) and softmax temperature (B) on Trastuzumab experiment. Text annotations next to each marker denote the hyperparameter used for each experiment.
Figure 10: Wallclock time in seconds for Trastuzumab.
Figure 11: In silico predicted probability of synthesizability for AbLang2 generated sequences, as a function of number of edits.
Figure 12: Additional in silico evaluation results for generated sequences: (A) OASis humanness percentile, (B) germline mutation bias, (C) isoelectric point, and (D) number of CDR mutations.